Within the cannabis industry, Nemus Bioscience’s team is unparalleled for a company of its size, putting it alongside larger competitors like GW Pharmaceuticals plc (NASDAQ:GWPH) in terms of talent. CEO John Hollister, MBA, leads the team at Nemus Bioscience with over 25 years of leadership experience in the pharmaceutical industry, from start-ups to blue chips. As a strategic consultant, he has worked with a variety of early stage companies to refine their plans, while he was involved in hands-on work with companies like GlaxoSmithKline plc (NYSE:GSK) and Amgen Inc. (NASDAQ:AMGN) bringing products through clinical trials. CMO Brian Murphy, MD, MPH, MBA, contributes more than 15 years of experience in drug development and evaluation to the team from both small and large companies. With a background in business, academia, and medicine, Dr. Murphy has diverse talents and a unique perspective on the market from all angles. CFO Elizabeth Berecz, MA, CPA, rounds out the team with over 20 years of experience holding senior level positions in both private and public companies. With significant experience in strategic planning, financial reporting, and global systems integrations for companies of various sizes, she brings an air of financial credibility to the micro-cap company, which further differentiates itself in a space that remains somewhat foreign to investors. Looking Ahead to the Future Nemus Bioscience’s exclusive university partnership has provided it with a proprietary delivery mechanism for cannabinoids and a pro-drug platform that could allow the therapy to evade first-pass metabolism by the liver thereby optimizing delivery in a more predictable and reliable way.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/nemus-unlocks-cannabinoid-potential-unique-142000586.html

By admin